Hans‐Christian Kolberg
A5021298305- Breast Cancer Treatment Studies
- Advanced Breast Cancer Therapies
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Breast Lesions and Carcinomas
- PARP inhibition in cancer therapy
- Estrogen and related hormone effects
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- BRCA gene mutations in cancer
- Statistical Methods in Clinical Trials
- Breast Implant and Reconstruction
- Biosimilars and Bioanalytical Methods
- Cancer Cells and Metastasis
- Monoclonal and Polyclonal Antibodies Research
- Bioinformatics and Genomic Networks
- Chronic Lymphocytic Leukemia Research
- Cancer Risks and Factors
- Cancer Diagnosis and Treatment
- Gene expression and cancer classification
- Cancer survivorship and care
- Radioactive Decay and Measurement Techniques
- DNA Repair Mechanisms
- Cancer-related Molecular Pathways
- Global Cancer Incidence and Screening
Marienhospital Bottrop
2016-2025
University Hospital and Clinics
2023
Johannes Gutenberg University Mainz
2023
St. Josefs Hospital
2023
Marienhospital Stuttgart
2023
Klinik für Frauenheilkunde
2004-2022
Comprehensive Cancer Center Erlangen
2016
Universitätsklinikum Erlangen
2016
Friedrich-Alexander-Universität Erlangen-Nürnberg
2016
Ludwig-Maximilians-Universität München
2015
Normal splenic size in infants and children: sonographic measurements.H K Rosenberg, R I Markowitz, H Kolberg, C Park, A Hubbard D BellahAudio Available | Share
Among patients with metastatic breast cancer (mBC), the frequency of germline mutations in susceptibility genes and clinical relevance these are unclear. In this study, a prospective cohort mBC was used to determine mutation rates for (BC) predisposition genes, evaluate characteristics mutations, assess influence on patient outcome.
The multicenter, randomized, phase IV, intergroup AGO-B WSG PreCycle trial (NCT03220178) evaluated the impact of CANKADO-based electronic patient-reported outcome (ePRO) assessment on quality life (QoL) in hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer (MBC) patients receiving palbociclib and an aromatase inhibitor + fulvestrant. CANKADO PRO-React, a European Union-registered medical device, is interactive autonomous...
Pembrolizumab is approved for the neoadjuvant/adjuvant treatment of early triple-negative breast cancer (TNBC) patients in combination with chemotherapy. The Keynote-522 trial used platinum As neoadjuvant nab-paclitaxel (nP) also highly effective patients, this study investigates response to nP-containing chemotherapy pembrolizumab.NeoImmunoboost (AGO-B-041/NCT03289819) a multicenter, prospective single-arm phase II trial. Patients were treated 12 weekly cycles nP followed by four...
Abstract This yearʼs 18th St. Gallen (SG) consensus conference on the treatment of early breast cancer (SGBCC: International Breast Cancer Conference) focused practice-oriented questions. The individual situation and risk-benefit assessment were discussed in great detail. As previous years, a German working group leading experts presented results international SGBCC 2023 against background recommendations – especially updated Arbeitsgemeinschaft Gynäkologische Onkologie e. V. (AGO) for...
Liquid biopsies are discussed to provide surrogate markers for therapy stratification and monitoring. We compared messenger RNA (mRNA) profiles of circulating tumor cells (CTCs) extracellular vesicles (EVs) in patients with metastatic breast cancer (MBC) estimate their utility management.Blood was collected from 35 hormone receptor-positive/HER2-negative MBC at the time disease progression 2 consecutive staging points. CTCs were isolated 5 mL blood by positive immunomagnetic selection, EVs 4...
In recent years, new targeted therapies have been developed to treat patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Some of these not just become the therapy standard but also led significantly longer overall survival rates. The cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) therapeutic for first-line therapy. Around 70 - 80% are treated a CDK4/6i. number biomarkers associated progression, clonal selection or...
Patients with first-line metastatic breast cancer (MBC) comprise patients de novo metastases (dnMBC) or recurrent disease after primary (rMBC). This analysis aimed to explore the prognostic value of dnMBC versus rMBC overall and particularly in subgroups according age metastasis site, addition other clinicopathological parameters a first-line, hormone receptor (HR)-positive, HER2-negative (HRpos/HER2neg) population. Within prospective PRAEGNANT MBC registry (NCT02338167), 508 HRpos/HER2neg...
Zusammenfassung Für Patientinnen wie auch Patienten mit hormonrezeptorpositivem (HRpos)/Human epidermal growth factor receptor 2- negativem (HER2neg) Mammakarzinom wurden in den letzten Jahren einige neue, zielgerichtete Therapien eingeführt. Einige dieser Behandlungen konnten sich nicht nur als neuer Therapiestandard etablieren, sondern führten zu einem signifikant verlängerten Gesamtüberleben. Insbesondere die Cyclin-dependent Kinase 4 and 6 Inhibitors (CDK4/6i) haben der ersten...
We investigated whether TK1 concentration or activity in the blood, drawn at baseline and under therapy, might have value for therapy management 110 hormone receptor-positive (HR+), HER2-negative (HER2-) metastatic breast cancer (mBC) patients treated with CDK4/6 inhibitors (CDK4/6i) and/or endocrine (ET). were not significantly correlated each other matched samples. In CDK4/6i cohort baseline, high associated a decreased PFS primary resistance. Longitudinal sampling revealed higher...
This study presents comprehensive real-world data on the use of anti-human epidermal growth factor receptor 2 (HER2) therapies in patients with HER2-positive metastatic breast cancer (MBC). Specifically, it describes therapy patterns trastuzumab (H), pertuzumab + (PH), lapatinib (L), and emtansine (T-DM1). The PRAEGNANT is a real-time, registry for MBC patients. All lines are documented. analysis utilization anti-HER2 as well sequences. Among 1936 PRAEGNANT, 451 were (23.3%). In set (417...
Abstract Background Single liquid biopsy analytes (LBAs) have been utilized for therapy selection in metastatic breast cancer (MBC). We performed integrative statistical analyses to examine the clinical relevance of using multiple LBAs: matched circulating tumor cell (CTC) mRNA, CTC genomic DNA (gDNA), extracellular vesicle (EV) and cell-free (cfDNA). Methods Blood was drawn from 26 hormone receptor-positive, HER2-negative MBC patients. mRNA EV were analyzed a multi-marker qPCR. Plasma...
Abstract Background Comprehensive data from prospective clinical trials have led to a high level of evidence establishing CDK4/6 inhibitors in combination with endocrine treatment (CDK4/6i + ET) as standard for the HER2-negative, hormone receptor-positive (HER2− HR+) breast cancer patients first-line advanced therapy setting. Data on patient populations that been treated real-world setting may provide an insight into changes characteristics and prognosis over time. Methods The were extracted...